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REGULATING CLINICAL RESEARCH: INFORMED 
CONSENT, PRIVACY, AND IRBS 
SHARONA HOFFMAN 
I. INTRODUCTION 
During the past two decades, the United States has experienced 
dramatic developments in the area of biomedical research. 1 Expanding 
budgets, 2 augmented computer capabilities, and the Human Genome 
Projece have all significantly enhanced research capabilities.4 
Consequently, the number of research projects conducted in this country is 
ever growing, 5 and the enrollment of an adequate number of human 
subjects is becoming an increasingly challenging task.6 In the words of 
one commentator, "never have so many human clinical trials been 
underway and offered so much promise for improving human health . . . 
[and] never have the economic and regulatory challenges been as great. 7" 
Copyright © 2002, Sharona Hoffman 
I See Beverly Woodward; Challenges to Human Subject Protections in US Medical 
Research, 282 JAMA 1947, 1948 (1999). 
2 See Harold Y. Vanderpool, Introduction and Overview: Ethics, Historical Case 
Studies, and the Research Enterprise, in THE ETHICS OF RESEARCH INVOLVING HUMAN 
SUBJECTS: FACING THE 21 5T CENTURY 1,13(Harold Y. Vanderpool ed., 1996) (hereinafter 
THE ETHICS OF RESEARCH] ("[F]unding for biomedical research from federal, state, local, 
philanthropic, and industry sources had reached the amazing sum of $22.5 billion by 
1990."); See also Gregg Easterbrook, What Went Right: Modest Gain, THE NEW REPUBLIC, 
Jan. 22,2001, at 12, 15 (explaining that the National Institutes of Health's (NIH) budget 
increased 111% during the Clinton presidency). 
3 See Leroy Hood & Lee Rowen, Genes, Genomes and Society, in GENETIC 
SECRETS: PROTECTING PRIVACY AND CONFIDENTIALITY IN THE GENETIC ERA 3 (Mark A. 
Rothstein ed., 1997). 
4 See Woodward, supra note 1, at 1948. 
Elizabeth Austin, Flying Double-Blind Would You Be Willing to Risk Your Health 
for Science? CHI. TRIB., Sept. 10, 2000, at 16, 18 ("An estimated 60,000 to 70,000 
[clinical] trials are being conducted at any given time in the United, States."). 
6 I d. See also, Kurt Eichenwald and Gina Kolata, Drug Trials Hide Conflicts for 
Doctors, N.Y. TIMES, May 16, 1999, at I. The article attributes the proliferation of drug 
trials in the 1990s to managed care and the restrictions it placed on drug prices. I d. Since 
drug companies were limited in the prices they could charge for each drug, they opted to 
increase the number of drugs they sold in order to maintain profitability. I d. Thus began the 
industry's''rush to drug development." Id. 
7 Michael J. Malinowski, Institutional Conflicts and Responsibilities in an Age of 
Academic-Industry Alliances, 8 WIDENER L. SYMP. J. 47, 47 (2001) (citation omitted). 
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Clinical research involving human participants is governed by federal 
regulations that have bl'!en promulgated by the Department of Health and 
Human Services (DHHS) and the Food and Drug Administration (FDA).8 
In light of the proliferation of medical research, however, an increasing 
number of critics are voicing serious concerns about inadequate 
enforcement of the regulations· and unacceptable research risks. 9 In recent 
years, several subjects have died as a result of treatment received in 
clinical trials and several well-publicized lawsuits have been filed against 
researchers, research institutions, and institutional review boards (IRBs ). 10 
The most prominent case is that of Jesse Gelsinger, an eighteen-year old 
man with a rare metabolic disease, who died . while undergoing 
experimental genetic therapr administered in a clinical study at the 
University of Pennsylvania. 1 In addition, a healthy research volunteer 
died as a res~lt of an experiment r_el~tin~ to asthma that was c?nd~cted at 
Johns Hopkins School of Medtcme. 1 Two recent lawsmts mvolve 
individuals who received an experimental melanoma vaccine in a clinical 
trial conducted at the University of Oklahoma Health Science Center in 
Tulsa 13 and patients who participated in blood cancer trials at the Fred 
21 C.F.R. §§ 50.1-56.124 (2002); 45 C.F.R. §§ 46.101-46.409 (2001). 
See Protecting Human Clinical Research Patients: Hearing on Institutional 
Review Boards (IRBS) Before the House Comm. on Gov 't Reform & Oversight Subcomm. 
on Human Resources, 105'h Cong. (1998) (statement of George Grob, Deputy Inspector 
General for Evaluation and Inspections, Department of Health and Human Resources), 
available at 1998 WL 12761511 (hereinafter 1998 Hearing). 
10 IRBs are committees designated by research institutions to review, approve, and 
periodically monitor biomedical research studies. 21 C.F.R § 56.102(g) (2002); See also 45 
C.F.R. § 46.102(g)(2001). 
11 Rick Weiss & Deborah Nelson, Teen Dies Undergoing Experimental Gene 
Therapy, WASH. PosT, Sept. 29, 1999, at AI; Gelsinger v. Trustees of the Univ. of 
Pennsylvania, No. 000901885 (Philadelphia County Ct. Com. Pl.) (filed Sept. 18, 2000). 
The lawsuit was settled on Nov. 3, 2000 and the details of the agreement were not released. 
See Alison Schneider, U. of Pennsylvania Settles Lawsuit Over Gene-Therapy Death, 
CHRON. HIGHER Eouc., Nov. 6, 2000, available at htip:/lchronicle.comldailyl 
2001/ll/2000//0602n.htm .. 
12 Robert Steinbrook, Protecting Research Subjects - The Crisis at Johns Hopkins, 
346 N. ENGL. J. MED. 716-720 (2002). In the study, subjects were instructed to inhale a 
drug called hexamethonium that causes airways to constrict, and physicians observed the 
subject's airways as they took deep breaths. !d. at 717. 
13 Robertson v. McGee, No. 4:01-CV-60 (N.D. Okla.) (filed Jan. 29, 2001). The 
plaintiffs seek damages arising from alleged failures to comply with the federal regulations 
that govern biomedical research. Id 
2002] REGULATING CLINICAL RESEARCH 73 
Hutchinson Cancer Research Center in Seattle. 14 Intensifying concerns 
about both human subject welfare and potential liability are stimulating 
urgent calls for regulatory reforms. 
Part I of this Article provides a brief historical overview of Twentieth 
Century research abuses and the development of regulatory oversight in the 
United States. Part II discusses informed consent, IRBs, and the 
regulations that govern them. Part III analyzes contemporary deficiencies 
in the regulatory system. Finally, Part IV offers recommendations for 
reform. 
II. A HISTORICAL OVERVIEW OF RESEARCH ABUSES AND THE 
DEVELOPMENT OF RESEARCH REGULATIONS 
During World War II, the Nazis conducted large-scale, experiments on 
concentration camp prisoners that were designed not . only to gather 
medical data, but also to torture and kill the subjects. In some camps, 
German doctors infected numerous healthy inmates with yellow fever, 
smallpox, ~bus, cholera, and diphtheria germs that caused hundreds of 
them to die. 5 In other camps Nazi physicians conducted experiments 
relating to high altitude, malaria, fret)zing, mustard fflas, bone 
transplantation, sea water, sterilization, and incendiary bombs. The full 
scope and ghastliness of the Nazi medical experimentation was revealed 
and documented during the Nuremberg Trials after World War II. 17 
In the United States, medical research was conducted for many 
decades without any regulatory oversight. 18 Perhaps not surprisingly, in an 
environment devoid of regulation and monitoring, an alarming number of 
14 Wright v. Fred Hutchinson Cancer Research Ctr, No. 01-2-008376 (Kitsap 
County Sup. Ct. filed Mar. 29, 2001). The complaint alleges that subjects were not fully 
informed of the study's risks, and that the investigators were unduly influenced by the 
allure of potential financial profits. Jd. Eighty of the eighty-two individuals who 
participated in the trial between 1981 and 1993 died. Jd.; Vida Foubister, Lawsuits have 
doctors wary, but not quitting research yet, 44 AM. MED. NEWS, Apr. 16,2001, at 1-2. 
15 ALLEN M. HORNBLUM, ACRES OF SKIN: HUMAN EXPERIMENTS AT HOLMSBURG 
PRISON 75 (1998). 
16 ld. at 75-77. 
17 The Nuremberg Trials commenced on November 20, 1945 at the Palace of Justice 
in Nuremberg, Germany. Fifteen of the twenty-three defendants were found guilty of"war 
crimes and crimes against humanitY," and seven of them were sentenced to death. See 
Alexander Mitscherlich & Fred Mielke, Epilogue: Seven Were Hanged, in THE NAZI 
DOCTORS AND THE NUREMBERG CODE 105-06; Bernard Meltzer, \'War Crimes": The 
Nuremberg Trial and the Tribunal for the Former Yugoslavia, 30 VAL. L. REv. 895, 896 
(1996). 
18 Vanderpool, supra note 2, at 8. 
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research abuses occurred in this country as well. 19 In the early 1950s, 
nearly one hundred percent of participants in Phase I clinical trials, the first 
and riskiest phase of human research studies/0 were prisoners?1 In Ohio, 
for examJ:>le, live cancer cells were introduced into both forearms of many 
prisoners.22 Two weeks after the injection, the affected area of one arm 
would be surgically removed for study, while the malignant cells were left 
in the other forearm for further observation.23 At the Ionia State Hospital 
in Michigan, at least 142 inmates were recruited for secret CIA 
psychological experiments. 24 As late as 1969, eighty-five percent of new 
medications were still tested on prisoners. 25 
Research abuses in the decades following WWII were not limited to 
the prison environment but also involved other vulnerable populations.26 
For example, patients at the Jewish Chronic Disease Hospital in Brooklyn 
had live cancer cells injected under their skin, and retarded children in the 
Willowbrook State School on Staten Island were infected with a mild 
strain of hepatitis.27 The experiments were done without the subjects' 
knowledge or consent. 28 . 
In 1972, news of the notorious Tuskegee syphilis study highlighted the 
problem of mistreatment of medical research subjects in the United 
States.29 The Tuskegee study, whose participants were all African-
American men, was conducted from 1932 until the beginning of the 1970s 
and sought to analyze the natural progression of untreated syphilis. 30 The 
researchers, therefore, did not provide patients with penicillin, an antibiotic 
that is a fully effective cure for syphilis and was widely available as early 
19 
20 
I d. 
See 21 C.F.R. § 312.21(a) (2002). Human research studies are often called 
"clinical trials." !d. 
21 
22 
23 
HORNBLUM, supra note 15, at 43. 
HORNBLUM, supra note 15, at 93. 
HORNBLUM, supra note 15, at 93. 
24 HORNBLUM, supra note 15, at 95. , 
25 Kathleen Schroeder, A Recommendation to the FDA Concerning Drug Research 
on Prisoner, 56 S. CAL. L. REv. 969, 971 (1983). 
26 Henry K. Beecher, Ethics and Clinical Research, 274 NEW ENG. J. MED. 1354, 
1354-60 (1966). 
27 
28 
!d. at 1358; Vanderpool, supra note 2, at 9. 
Vanderpool, supra note 2, at 9. 
29 See Colleen M. McCarthy, Note, Experimentation on Prisoners: The Inadequacy 
of Voluntary Consent, 15 NEW ENG. J. ON CRIM. & Clv. CONFINEMENT 55, 58 (1989); See 
also Vanderpool, supra note 2, at 9. The first report of the study appeared in a July 1972 
article by Jean Heller entitled Syphilis Victims in US. Study Went Untreated for 40 Years. 
30 WILLIAM J. CURRAN ET AL., HEALTH CARE LAW AND ETHICS 276 (5th ed. 1998). 
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as 1953.31 The subjects, who believed they were receiving adequate care, 
continued to suffer unnecessarily from the debilitating effects of the 
disease.32 
The federal government finally responded to publicity concerning 
research abuses by promulgating oversight regulations. The FDA and the 
National Institutes ofHealth (NIH) developed internal policy guidelines in 
1966 and 1971, respectively, and these became federal regulations in 
1974.33 The National Commission for the Protection of Human Subjects in 
Biomedical and Behavioral Research was established through the National 
Research Act of 197434 and operated for four years, until 1978.35 Pursuant 
to the Commission's recommendations; the federal regulations underwent 
revision in 1981, and they have remained in effect since then. 36 
III. THE FEDERAL REGULATIONS THAT GOVERN IRBs AND 
INFORMED CONSENT 
A. What Is Regulated? 
Research studies, generally termed "clinical trials," for the 
development of new drugs and devices are regulated by the FDA.37 
Medications that are the focus of study in clinical trials are called 
investigational new drugs (INDs).38 Clinical trials that involve treatments 
!d.; Vanderpool, supra note 2, at 9. 
CURRAN ET AL., supra note 30, at 276. 
Vanderpool, supra note 2, at 10. 
31. 
32 
33 
34 See National Research Service Award Act of 1974, Pub. L. 93-348, 88 Stat. 342 § 
201; McCarthy, supra note 29, at 58-59. 
35 BARUCH A. BRODY, ETHICAL ISSUES IN DRUG TESTING, APPROVAL AND PllJCING 
103 (1995). 
36 Vanderpool, supra note 2, at 10. 
37 21 C.F.R. § 7.3(t) (2002) ("Product" m\!anS an article subject to the jurisdiction of 
the Food and Drug Administration, including any food, drug, and device intended for 
human or animal use .... ) 
38 21 C.F.R. § 312.23(a) (2002). Medical research for drugs is conducted in three or 
four phases of clinical trials. See generally§ 312.23. In Phase I, the new drug or treatment 
is given to patients or healthy individuals to determine its toxicity, most effective method of 
administration, and safe dosage range. !d. Participants in the trial receive increasing 
dosages of the substance in order to determine its metabolism, absorption, and side effects 
and to gain early evidence of its effectiveness, if possible. Id. Phase I clinical trials 
generally involve only 20 to 80 subjects, last about a year, and have a very high failure rate. 
Seventy percent of drugs submitted for Phase I clinical trials fail to progress to Phase II. See 
Veronica Henry, Problems with Pharmaceutical Regulations In the United States, 14 J. 
LEGALMED. 617 (1993). 
(continued) 
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other than drugs and devices, such as surgery or bone marrow transplants, 
are not regulated by the FDA and are subject to DHHS regulation only if 
they are "conducted, supported or otherwise subject to regulation by any 
federal department or agency .... "39 
B. IRBs 
Research that is conducted, supported, or regulated by DHHS, the 
FDA, or another federal agency must be reviewed by an IRB.40 An IRB is 
a committee designated by an institution to provide initial approval and 
periodic monitoring for biomedical research studies.41 The IRB's primary 
purpose is to protect the rights and welfare of human subjects. 42 The IRB 
reviews a document known as the "protocol" for each proposed clinical 
trial, which describes the objectives of the research, its procedures, 
eligibility requirements for participants, the number of subjects to be 
tested, and other details.43 The material submitted to the IRB also includes 
a document known as the "informed consent" form, which is given to all 
potential enrollees in order to provide them with a detailed explanation of 
the clinical trial and an opportunity to agree to participation in the study.44 
Phase H trials are designed to determine the effectiveness of the therapy. /d. The 
treatment is administered to patients suffering from the condition for which the therapy is 
intended. The trial often involves I 00 to 300 people and lasts about two years. /d. 
Approximately 33% of drugs submitted for clinical trials fail in Phase II testing. /d. 
Phase III clinical trials are conducted only after the treatment has proven effective 
through Phase I and II trials. /d. The third phase attempts to assess the medical results of the 
experimental therapy in comparison with standard therapy or no therapy at all. /d. Phase Ill 
studies usually involve several hundred to several thousand patients and last about three 
years. /d. 
The FDA may also require post marketing or Phase IV clinical trials. /d. These studies 
are designed to determine the existence of less common adverse reactions, the effect of the 
drug on morbidity or mortality, or the effect of the drug on a particular patient population, 
such as children. See 21 C.F.R. §§ 312.21, 312.85 (2002); See also Veronica Henry, 
Problems with Pharmaceutical Regulation in the United States, 14 J. LEGAL MED. 617, 
621-22 (1993). 
39 45 C.F.R. § 46.101(a) (2001); See also Richard S. Saver, Note, Reimbursing 
New Technologies: Why Are the Courts Judging Experimental Medicine?, 44 STAN. L. 
REv. 1095, 1110-11 (1992); Norman Daniels & James E. Sabin, Last Chance Therapies and 
Managed Care: Pluralism, Fair Procedures, and Legitimacy, HASTINGS CENTER REPORT, 
Mar.-Apr. 1998, at 29. 
40 21 C.F.R. §§ 56.101(a), 56.103 (2002); 45 C.F.R. § 46.101(a) (2001). 
41 21 C.F.R § 56.102(g) (2002); 45 C.F.R. § 46.102(g) (2001). 
42 21 C.F.R. § 56.102(g) (2002). 
43 21 C.F.R § 56.115 (a) (2) (2002); 45 C.F.R. § 46.115 (a) (I) (2001). 
44 21 C.F.R. § 50.20 (2002); 45 C.F.R. § 46.116 (2001). 
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After the IRB approves the informed consent form, all those who wish to 
become human subjects must sign a copy of the document, affirming the 
voluntariness oftheir choice.45 
The structure and duties of IRBs are governed by the DHHS and FDA 
regulations.46 Each IRB must be composed of at least five members with 
diverse cultural and ethnic backgrounds, and both men and women should 
be included. 47 At least one member of the IRB should be a person whose 
principal concerns are in the scientific realm, and one individual's 
expertise should be nonscientific (e.g. a lawyer or minister). 48 
Furthermore, to enhance its objectivity, each IRB must include at least one 
member who is not otherwise affiliated with the research facility and who 
has no immediate family members affiliated with the entity.49 According to 
DHHS's Office for Protection from Research Risks (OPRR), now renamed 
the Office for Human Research Protection (OHRP), eighty-six percent of 
IRB members in 1995 were affiliated with academic research institutions 
as full-time faculty (56%), clinical and research staff (18%), and 
administrators (6%).50 Academic institutions do not compensate IRB 
members for their work, and thus these individuals must volunteer their 
time without receiving payment or relief from other job duties. 51 
Unless an expedited review is conducted, research protocols must be 
reviewed at IRB meetings at which a majority of members are present, 
including a member whose expertise is nonscientific.52 Decisions 
concerning approval of each study are made by majority vote. 53 
The IRB may approve, disapprove, or require modifications to the 
proposed research activities. 54 Investigators must be given written 
notification of the IRB's decisions, and IRBs are required to monitor the 
clinical trials they approve at intervals of at least once a year, or more 
45 
46 
47 
48 
49 
21 C.F.R. § 56.111(a)(4) (2002); 45 C.F.R. § 46.111(a)(4) (2001). 
21 C.F.R. §56 101 (a) (2002); 45 C.F.R § 46.101 (a) (2001). 
21 C.F.R. § 56.107(a) (2002); 45 C.F.R. § 46.l07(a)-(b) (2001). 
21 C.F.R. § 56.107(c) (2002); 45 C.F.R. § 46.l07(c) (2001). 
21 C.F.R. § 56.107(d) (2002); 45 C.F.R. § 46.107(d) (2001). 
50 JAMES BELL et al., EVALUATION OF NIH IMPLEMENTATION OF SECTION 491 
OF THE PUBLIC HEALTH ACT, MANDATING A PROGRAM OF PROTECTION FOR 
RESEARCH SUBJECTS, FINAL REPORT 17 ( 1998). 
51 Kerry Burke, Loose-Fitting Genes: The Inadequacies in Federal Regulation of 
Institutional Review Boards, 3 B.U. J. SCI. & TECH. L. 10, 38 (1997). 
52 21 C.F.R. § 56.108(c) (2002); 45 C.F.R. § 46.108(b) (2001). 
53 21 C.F.R. § 56.l08(c) (2002); 45 C.F.R. § 46.l08(b) (2001). 
54 21 C.F.R. § 56.l09(a) (2002); 45 C.F.R. § 46.109(a) (2001). 
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frequently, depending on the severityofthe risks entailed.ss This periodic 
monitoring is known as "continuing review."56 
Before approving a clinical trial, the IRB must ensure that· specific 
criteria are met. These include: (1) risks to participants are minimized; (2) 
risks to subjects are reasonable in light of anticipated benefits; and (3) 
selection of participants is equitable, and the protocol is sensitive to the 
particularized problems of research involving vitlnerable populations, such 
as children, prisoners, pregnant women, mentaHr disabled individuals, or 
economically or educationally deprived persons. 5 
C. Informed Consent 
The contents of informed consent forms are also govffrned by the 
federal regulations. The informed consent document must be written in 
language that is accessible to subjects. 58 Informed consent may not include 
language that waives any of the subject's rights or releases the institution 
or research personnel from liability for negligence.59 The regulations 
further require that informed consent be obtained in writing from each 
enrollee, though they allow for certain exceptions. 60 
The regulations specify certain data that must be featured on the 
informed consent document. This information includes a description of the 
research, an explanation of risks, benefits, and alternatives, a discussion of 
confidentiality, a list of contact people, and· a statement that participation is 
voluntary and may be discontinued at any time.61 
55 
56 
57 
58 
59 
60 
61 
21 C.F.R. § 56.109(e)-(t) (2002); 45 C.F.R. § 46.109(d)-(e) (2001). 
21 C.F.R. § 56.109(t) (2002); 45 C.F.R. § 46.109(e) (2001). 
21 C.F.R. § 56.11l(a) (2002); 45 C.F.R. § 46.11l(a) (2001). 
21 C.F.R. § 50.20 (2002); 45 C.F.R. § 46.116 (2001). 
21 C.F.R. § 50.20 (2002); 45 C.F.R. § 46.116 (2001). 
21 C.F.R. § 50.27 (2002); 45 C.F.R. § 46.117 (2001). 
21 C.F.R. § 50.25(a) and (b) (2002); 45 C.F.R. § 46.116(a) and (b) (2001). The 
provisions read as follows: 
(a) Basic elements of informef:l consent. [I]n seeking informed consent the following 
information shall be provided to each subject: 
(I) A statement that the study involves research, an explanation of the purposes of the 
research and the expected duration of the subject's participation, a description of the 
procedures to be followed, and identification of any procedures which are experimental; 
(2) A description of any reasonably foreseeable risks or discomforts to the subject; A 
description of any benefits to the subject or to others which may reasonably be expected 
from the research; 
(3) A disclosure of appropriate alternative procedures or courses of treatment, if any, 
that might be advantageous to the subject; 
(4) A statement describing the extent, if any, to which confidentiality of records 
identifying the subject will be maintained; 
(continued) 
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D. Research Involving Only Existing Medical Records Or Tissue Samples 
In some cases investigators conduct research that does not involve 
treatment of any human subject. Instead, the research entails the study of 
existing medical records or tissue sai11ples.62 For example, researchers 
might want to determine whether patients who have . a particular type of 
cancer suffered certain symptoms before their diagnosis and might attempt 
to make that determination through an examination of their recorded 
medical histories. Investigators are not required to obtain informed 
consent from subjects for such research if the information is publicly 
available or if the researcher will record the data in a way that will make it 
impossible for subjects to be identified. 63 
In addition, the regulations provide that an IRB may waive informed 
consent requirements if it finds "[t]hat the research presents no more than 
(5) For research involving more than minimal risk, an explanation as to whether any 
compensation and an explanation as to whether any medical treaJments are available if 
injury occurs and, if so, what they consist of or where further information may be 
obtained; 
(6) An explanation of whom to contact for answers to pertinent questions about the 
research and research subjects' rights, and whom to contact in the event of a research-
related injury to the subject; and 
(7) A statement that participation is voluntary, refusal to participate will involve no 
penalty or loss of benefits to which the subject is otherwise entitled, ;md the subject 
may discontinue participation at any time without penalty or Joss of benefits to which 
the subject is otherwise entitled. 
(b) Additional elements of informed consent. When appropriate, one or more of the 
following elements of information shall also be provided to each subject: 
(I) A statement that the particular treatment or procedure may involve risks to the 
subject (or to the embryo or fews, if the subject is or may become pregnant) which are 
currently unforeseeable; 
(2) Anticipated circumstances under which the subject's participation may be 
terminated by the investigator without regard to the subject's consent; 
(3) Any additional costs to the subject that may result from participation in the 
research; 
(4) The consequences of a subject's decision to withdraw from the research and 
procedures for orderly termination of participation by the subject; 
(5) A statement that significant new finding developed during the course of the 
research which may relate to the subject's willingness to continue participation will be 
provided to the subject; and 
(6) The approximate number of subjects involved in the study. 
45 C.F.R. § 46.116(a) and (b) (2001). 
62 45 C.F.R. § 46.101 (b)(4) (2001). 
63 Jd. 
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minimal risk of harm to subjects and involves no procedures for which 
written consent is normally required outside of the research context. "64 
Accordingly, in limited circumstances in which subject welfare will not be 
compromised, this provision could allow for the use of identifiable medical 
records without subject consent.65 
IV. DEFICIENCIES IN THE REGULATORY SYSTEM 
A. IRB Workloads 
A 1998 statement issued by the Office of Inspector General of the U.S. 
Department of Health and Human Services (OIG) was highly critical of 
contemporary research oversight.66 The OIG stated that the enormous 
workloads of many IRBs currently prevent them from adequately 
performing their review functions. A follow-up report issued by the Office 
of Inspector General in April of 2000 concluded that in the intervening two 
years, only minimal progress had been made to diminish the workload 
pressures of IRBs.67 The number of initial reviews conducted by IRBs 
increased by an average of forty-two percent from 1993 to 1998, and some 
IRBs review up to 2,000 protocols per year.68 Some IRBs also receive 
200 or more reports of adverse events each month concerning the clinical 
trials they oversee.69 An external review conducted at Johns Hopkins 
University after the death of a healthy human subject revealed that until 
June of 2001 a single IRB, meeting every two weeks, was responsible for 
the approval of 800 new protocols and the annual reviews they generated. 70 
The reviewers emphatically stated: "[w]e view this as grossly 
64 45 C.F.R. § 46.117(c)(2) (2001). 
65 45 C.F.R. Pts. 160, 164; Jennifer Kulynych & David Korn, The Effect of the New 
Federal Medical-Privacy Rule on Research, 346 N. ENGL. J. MED. 201, 201-04 (2002) 
(discussing new privacy rule that became effective on Apr. 14, 2001. Most health care 
providers will be required to'~omply with the new rule by Apr. 2003); See also Standards 
for Privacy of Individually Identifiable Health Information, available at 
http://www.hhs.gov/ocr/hipaalfinalmaster.html (last visited July 9, 2001). The use and 
disclosure of protected health information is addressed in 45 C.F.R. §§ 164.501, 164.508(f), 
and 164.512(i). 
66 See 1998 Hearing, supra note 9. 
67 Protecting Human Research Subjects: Status of Recommendations (2000) (Office 
of [nspector General, Department of Health and Human Services), available at 2000 WL 
553517, at *3. 
68 !d. at *5. The average local lRB meeting was found to last approximately 2.5 
hours and to include 18 initial reviews, 9 expedited reviews, 43 amendments to protocols 
and 21 adverse-event reports. !d. at *6. 
69 !d. 
70 Steinbrook, supra note 12, at 719. 
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inadequate."71 As noted above, most IRB members have full time jobs on 
the faculties or staffs of research institutions,72 and are not paid for their 
IRB services or relieved of other work duties.73 Consequently, the time 
members can spend on IRB work is limited, and IRBs generally meet only 
once or twice a month for a few hours.74 · 
OPRR expressed concern that the IRBs' work is also hampered by 
deficient expertise and resources. 75 Some IRB members lack in-depth 
understanding of the federal regulations governing biomedical research, 
and IRBs do not have the space, privacy, and level of staff support 
necessary to perform their duties adequately. 76 Small IRBs may have only 
one salaried staff member to coordinate all IRB activities and perform 
administrative tasks. 77 
If IRBs become frequent defendants in lawsuits, 78 the IRB system may 
be fundamentally threatened. Since IRBs rely heavily on the work of 
volunteers, they may find it difficult to recruit members in the future. 
Physicians who are concerned about potential liability may be very 
reluctant to offer their services to IRBs.79 
B. Flaws In The Informed Consent Process 
An increasing volume of evidence indicates that the informed consent 
process is severely flawed in many cases. Often, human subjects either 
are given insufficient information or do not comprehend the data they 
receive. 
The 1998 OIG statement was very critical of informed consent 
procedures. 80 It noted, for example, that a 1995 Advisory Commission on 
71 
72 
73 
74 
75 
Steinbrook, supra note 12, at 719. 
See BELL, supra note 50 and accompanying text. 
Steinbrook, supra note 12, at 717; Burke, supra note 51, at 38. 
Steinbrook, supra note 12, at 719. 
U.S. DEP'T OF HEALTH & HUMAN SERVS., OFFICE FOR HUMAN RESEARCH PROTS., 
OHRP COMPLIANCE ACT!VlTIES: COMMON FINDINGS AND GUIDANCE (Sept. I, 2000), 
available at http://ohrp.osophs.dhhs.gov/references/findings.pdf. [hereinafter OHRP]. 
76 ld. 
77 
78 
2001). 
1998 Hearing, supra note 9. 
See e.g., Robertson v. McGee, No. 4:01-CV- 60 (N.D. Okla.) (filed Jan. 29, 
79 Alan Milstein, an attorney who has filed several lawsuits against physician 
investigators on behalf of clinical trial participants, has publiciy criticized IRBs as sharing 
the blame for alleged injuries to human subjects. In one article he stated that "[I]n our 
major institutions, where you've got Nobel scientists and Nobel doctors and well-regarded 
professors, the IRBs more or less simply rubber-stamp whatever protocol one of these men 
put before them." Foubister, supra note 14, at I. 
80 See 1998 Hearing, supra note 9. 
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Human Radiation Experiments found, after interviewing actual subjects 
that few realized they were involved in research, and many had little 
understanding of the informed consent forms they had signed.81 
Commonly; the problem is confusion about the differences between 
research and clinical treatment.82 While some research subjects are healthy 
volunteers who would not otherwise seek medical treatment, many are 
patients with particular illnesses who are recruited for cliniCal research by 
their treating physicians. These patients are vulnerable to a phenomenon 
known as the "therapeutic misconception. "83 Because they are sick and are 
recruited for enrollment by their doctors, they become convinced that their 
research participation will be of definite medical benefit to them. These 
patients are therefore resistant to explanations that treatments involved in 
clinical trials are unproven and experimental, no matter how clearly and 
explicitly these explanations are given. 
Numerous studies have focused on the issue of informed consent and 
have revealed very troubling evidence concerning the ability of research 
subjects toprovide valid consent.84 In a labor-induction study with fifty-
two participants, thirty-nine percent of the women were found to be 
unaware that they were participating in a research study although all had 
81 See 1998 Hearing, supra note 9. 
82 CHARLES LIDZ ET AL., INFORMED CONSENT: A STUDY OF DECISIONMAKING IN 
PSYCHIATRY 28 (1984); See also Paul S. Appelbaum et al., False Hopes and Best Data: 
Consent to Research and the Therapeutic Misconception, 17 HASTINGS CENTER REP. 20 
(1987). The authors explain the problem as follows: 
!d. 
Most people have been socialized to believe that physicians (at least 
ethical ones) always provide personal care. It may therefore be very 
difficult, perhaps nearly impossible, to persuade subjects that this 
encounter is different, particularly if the researcher is also the treating 
physician, who has previously satisfied the subject's ·expectations of 
personal care. Further, insofar as much clinical research involves 
persons who are acutely ill and in some distress, the well-known 
tendency of patients to regress and entrust their well-being to an 
authority figure would undercut any effort to dispel the therapeutic 
misconception. 
83 Evan G. DeRenzo et al., Assessment of Capacity to Give Consent to Research 
Participation: State-of-the-Art and Beyond, I J. HEALTH CAREL. & POL'Y 66, 72 (1998); 
See also Holly A. Taylor, Barriers to Informed Consent, 15 SEMINARS IN ONCOL. NuRS. 89, 
91 (1999) (noting that oncology patients often perceive enrollment in a research protocol as 
their last chance to receive effective treatment). 
84 DeRenzo, supra note 83, at 69; Janet Fleetwood, Conflicts of Interest in Clinical 
Research: Advocating/or Patient-Subjects, 8 WIDENERL. SYMP. J 105, 108 (2001). 
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signed informed consent forms. 85 Even those who realized they were 
research subjects often misunderstood essential aspects of the study and 
their role in it. 86 
Several investigators asked fifty cancer patients to review a 
hypothetical consent form for participation in a placebo-controlled clinical 
trial. 87 Subjects were asked to interpret four different statements in the 
consent form.88 Depending on the statement, the subjects provided 
incorrect answers twenty-six to fifty-four percent of the time.89 
In another survey, forty-seven percent of responding researchers 
indicated that they thought few of their subjects, enrolled in multinational 
studies in the 1980s, knew they wete participating in controlled 
experiments, even though they had given written consent.90 In two 
additional studies, over three quarters of physicians who were questioned 
believed that subjects rarely understood all the data given to them.91 
The difficulty of obtaining informed consent is exacerbated by the fact 
that informed consent documents are generally written in language that is 
technical and sophisticated and consequently inappropriate for the intended 
audience.92 While many informed consent document require a college 
85 Bradford H. Gray, Complexities of Informed Consent, 437 ANNALS AM. ACAD. 
PoL. & Soc. Sci. 37, 43 (1978). Gray states that the women's misunderstanding is 
attributable to several factors "including the generally low educational levels of the unaware 
subjects, the investigator's delegation to subordinates of the task of obtaining consent, 
seeking consent in the labor room, and providing little oral explanation - sign this and we 
can get started." Id. 
86 BRADFORD H. GRAY, HUMAN SUBJECTS IN MEDICAL EXPERJMENTATION 103 
(1975); See also Angela Estey et al., Are Research Subjects Able to Retain the Information 
They Are Given During the Consent Process?, 3 HEALTH L. REv. 37 (1994). A study of29 
subjects from two clinical trials at the University of Alberta Hospitals revealed that 14 of 
them were unable to describe acclirately the type of research study in which they were 
enrolled and 17 could not list any risks associated with participation in the trial although 
risks had been explicitly explained to them. Id. at 40. 
87 H. J. Sutherfand et al., Are We Getting Informed Consent for Patients with 
Cancer?, 83 J. R. Soc. MED. 439 (1990). 
88 I d. at 440. 
89 Jd. at 441. 
90 Sarah J.L. Edwards et al., The Ethics of Randomized Controlled Trials from the 
Perspectives of Patients, the Public, and Healthcare Professionals, 317 BRJT. MED. J. 1209, 
1209 (1998). 
91 Id. at 1209-10. 
92 Jay Katz, Human Experimentation and Human Rights, 38 ST. LoUis U. L.J. 7, 36 
(1993); See also Christopher Daugherty et al., Perceptions of Cancer Patients and Their 
Physicians Involved in Phase I Trials, 13 J. CLIN. ONCOL. 1062, 1065 (1995); Daugherty 
found that the cancer patients' educational levels significantly influenced their ability to 
· (continued) 
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level reading comprehension ability,93 the average American has only an 
eighth grade reading comprehension level.94 Rather than providing useful 
explanations for patients, the forms often serve to educate only the 
medically trained IRB members who review them;95 
The challenge of obtaining genuine consent from subjects has had 
grave consequences for some institutions. During 1998 and 1999, OPRR 
suspended federal research funding at Chicago's Rush-Presbyterian-St. 
Luke's Medical Center, the West Los Angeles VA Medical Center, Duke 
University Medical Center, the University of Illinois at Chicago, and six 
Universi~ of Colorado institutions, all ofwhich are well-regarded research 
facilities. 6 In January of 2000, research activities were suspended at the 
University of Pennsylvania and the University of Alabama at 
Birmingham.97 Prominent among the violations for which these entities 
recall correctly the purpose of the phase I trials for which they were eligible to enroll. 
While 71% of college educated patients were able to state the purpose of phase 1 trials, only 
20% of those without a college degree could do so. Similarly, Casselith discovered that 
patients with less than a high school education had difficulty remembering information 
about a research protocol in which they had just consented to participate . Id Barrie R. 
Cassileth et al., Informed Consent- Why Are Its Goals Impelfectly Realized?, 301 N. ENGL. 
J. MED. 896, 898 {1980). 
93 Holly Taylor, supra note 83, at 93 (noting that "the average consent form is 
written at a level that requires at least a high school education or higher"); Henry W. 
Riecken & Ruth Ravich, Informed Consent to Biomedical Research in Veterans 
Administration Hospitals, 248 JAMA 344, 346 (1982) (noting that "most of the consent 
forms are written in language that requires reading ability at the college level for 
comprehension of the investigator's purpose," and that only 27% of VA patients surveyed 
"had more than a high school education."). 
94 Terry C. Davis et al., Reading Ability of Parents Compared with Reading Level of 
Pediatric Patient Education Materials, 93 PEDIATRICS 460, 461-62 (1994); Stuart A. 
Grossman et al., Are Informed Consent Forms Thai Describe Clinical Oncology Research 
Protocols Readable By Most Patients and Their Families?, 12 J. CLIN. ONCOL. 2211, 2212 
(1994). 
95 See Davis, supra note 94; Grossman, supra note 94. 
96 Vida Foubister, More Centers Cited for Ethics Lapses in Research, AM. MED. 
NEWS, Nov. 1, 1999, at 8, 10; See also AMERICAN ASSOCIATION FOR THEADVANCEMENTOF 
SCIENCE, PROFESSIONAL ETHICS, Summer 1999, at 3 (noting that OPRR shut down 1,000 
human research studies at the University of Illinois at Chicago and investigated the 
University of South Florida's IRB). 
97 Marlene CimOQS, FDA cites violations, halts human gene therapy work at Penn, 
THE PLAIN DEALER, Jan. 22, 2000, at 12A; Jay Reeves, Order suspends university's 
medical research, THE PLAIN DEALER, Jan. 22, 2000, at 12A (reporting that the government 
suspended about 25% of research studies conducted at the University of Alabama at 
Birmingham). 
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were cited was the failure to obtain adequate informed consent from 
subjects.98 
B. Informed Consent Is Particularly Difficult To Obtain From Gravely Ill 
Patients 
Genuine informed consent is particularly difficult to obtain when the 
patients at issue suffer from life-threatening diseases. 99 The decision-
making capacity of gravely ill patients is often compromised by the 
emotional trauma of their illnesses or by various social and familial 
pressures. Consequently, those who have the most to gain or lose from 
receiving experimental treatment are also those who are least able to 
provide meaningful informed consent. 
Illness can be viewed as an "ontological assault" that undermines the 
patient's identity by "attacking the fundamental unity of mind and 
body."100 A patient suffering from multiple sclerosis described the 
experience of disease in these words: 
The most deeply held assumption of daily life is the 
assumption that I, personally, will continue to be alive and 
it is in light of this assumption that one engages in daily 
activities. The onset of illness, however, brings one 
concretely face-to-face with personal vulnerability .... 
Thus, the person who is ill . . . is unable readily to fit 
illness into the typified schema used to organize and 
interpret experience .... One finds oneself preoccupied with 
the demands of the here and now, confined to the present 
moment, unable effectively to project into the future. 101 
Commentators have noted that serious sickness creates in patients a 
strong desire to be cared for and to be free of the responsibility and stress 
of decision-making, as though they were once again children. 102 Many 
scholars have noted that the thought processes of those suffering from 
prolonged or serious illnesses are often impaired and have urged that 
rese~ch f:rotoc~ls involving such patients be subject to h~ightened IRB 
scrutmy. 1 3 One mformed consent study found that as the senousness of the 
98 Foubister, supra note 96, at 8, 1 0; Cimons, supra note 97, at 12-A; See also 
OHRP, supra note 75. 
99 
100 
101 
102 
Fleetwood, supra note 84, at l 07. 
MARK A. HALL, MAKING MEDICAL SPENDING DECISIONS 36 ( 1997). 
I d. at 28. 
I d. 
103 Alison Wichman, Protecting Vulnerable Research Subjects: Practical Realities 
of Institutional Review Board Review and Approval, I J. HEALTH CAREL. & PoL'Y 88, 93 
(1998) ("People suffering from prolonged or serious illnesses that are refractory to standard 
(continued) 
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illness increases, the ability of potential subjects to remember information 
relevant to their research participation decreases. 104 Seriously ill patients 
may experience depression, extreme anxiety, rage, denial, or desperation to 
find a cure, all of which may cloud their judgment and hamper their ability 
to evaluate the benefits and risks of a clinical trial. 105 
therapies, or for which there are no standard therapies, should be considered vulnerable 
particularly when they are willing to take ahy risk for even a remote possibility of relief."); 
DeRenzo et al., supra note 83, at 69, 78 ("(T]he majority of studies conclude that seriously 
ill research subjects have difficulties in many facets of providing ethically valid consent," 
and "Serious disease produces desperation .... [b]oth on the part of subjects and their 
families (that] can make persons vulnerable to manipulation"); George J. Annas, The 
Changing Landscape of Human Exp~rimentation: Nuremberg, Helsinki, and Beyond, 2 
HEALTH MATRIX 119, 134 (1992)("Terminally ill AIDS and cancer patients can be harmed, 
misused, and exploited"); D. Christian Addicott, Regulating Research on the Terminally Ill: 
A Proposal for Heightened Safeguards, 15 1. CONTEMP. HEALTH L. & PoL'Y 479, 493 
( 1999) ("(T]he terminally ill share a number of relevant characteristics with the vulnerable 
populations listed in the regulations, [and thus] an IRB would be well within its authority to 
treat the terminally ill as vulnerable"); Sarah Hewlett, Consent to Clinical Research -
Adequately Voluntary or Substantially Influenced?, 22 J. MED. ETHICS 232, 233 (1996) 
(noting that patients dealing with illness may experience a reduction in their autonomy due 
to a variety of factors related to the physiologic and psychological impact of illness). 
104 Monica H. Schaeffer et al., The Impact of Disease Severity on the Informed 
Consent Process in Clinical Research, 100 AM. J. MED. 261, 264 (1996). The study 
involved 127 subjects who were recruited from four different research protocols at the 
National Institute of Health. /d. Nine subjects had metastatic cancer for which all treatment 
had thus far failed and were offered a Phase I study. /d. Thirty-six subjects had recurrent 
ovarian cancer and were offered a Phase II trial. /d. Twenty eight subjects were infected 
with the HIV virus and were offered participation in a Phase III clinical trial. /d. Finally, 54 
subjects were healthy volunteers who were enrolled in positron emission tomography 
studies. See id. at 261-62. 
While the ability of patients to remember information associated with their clinical 
trials generally decreased as the severity of their illness increased, there were several 
exceptions to this finding. /d. at 264. Immediate retention of information regarding clinical 
trial procedures increased as the severity of illness increased. /d. In addition, Phase I and II 
subjects showed the best long-term retention, while Phase III participants and healthy 
volunteers retained the least on a long-term basis. /d. Finally, retention of information about 
alternative therapies was the same among the three groups of sick subjects. /d. 
See also Cassileth, supra note 92, at 898 (noting that "(b]edridden patients gave 
significantly fewer correct responses to each item on the recall test [concerning 
chemotherapy, radiation therapy, or surgery, to which they had consented the previous day] 
than did ambulatory patients"). 
105 Addicott, supra note 103, at 502-03; Hewlett, supra note 103, at 233. 
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It is clear that many IRBs inadequately perform their oversight 
functions. Their deficient performance, however, does not stem from 
deliberate misconduct or indifference towards the welfare of human 
subjects, but rather, from inadequate resources, unmanageable workloads, 
and, in some cases, insufficient expertise. 106 Alleviating these problems is 
essential to enhancing protection for clinical trial participants. 
An effective means of improving the functioning of IRBs would be the 
addition of more full-time, paid, professionals to their staffs. The size of 
the professional staff would vary in accordance with the workloads of the 
IRBs. The professional staff members should be charged with the review 
of all protocols that are submitted for initial approval, amendment, and 
continuing review to the IRB. One or two members of the IRB with 
relevant medical expertise should also read each protocol and provide 
comments to the staff. 107 The professional staff should then provide 
written reports to the full IRB membership, summarizing the protocol and 
their recommendations. The IRB volunteers would be responsible for 
reading the reports, asking follow-up questions, and voting on whether to 
approve the protocol. 
Under this system, each IRB member will not be required to read every 
page of every protocol, many of which are quite voluminous, and therefore 
IRB duties will become less burdensome. The system will also expedite the 
review process so that investigators will not have to wait several months 
for approval of their submitted proposals. Finally, professional staffs 
would assure that each protocol actually receives a thorough and 
systematic initial review and continued monitoring, which many 
commentators have suggested does not always occur when these tasks are 
left exclusively in the hands of well-meaning, but overworked 
volunteers. 108 
Additional funding would obviously be needed to support the hiring of 
adequate professional staffs. To obtain the necessary economic support, 
IRBs could charge commercial research sponsors fot review of their 
protocols. Similarly, if the research is sponsored by a governmental entity, 
the sponsor could be required to add a fixed sum or a small percentage to 
106 See Malinowski, supra note 7, at 63; Fleetwood, supra note 84, at 111. 
107 Thus, a protocol relating to cancer treatment would be reviewed by professional 
staff members and .by one or more oncologists, and a protocol relating to therapy for heart 
disease would be reviewed by one or more cardiologists in addition to the professional staff. 
108 See discussion supra Part liLA. 
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its grant in order to support IRB activities. 109 Nothing in the federal 
regulations prohibits the imposition of such charges. 
B. Informed Consent Procedures 
Professor Jay. Katz of Yale Law School has warned that obtaining true 
informed consent is an "inordinately difficult task." 110 He suggests that 
researchers must disclose to study participants at least the following data: 
(1) that the subjects are not only patients and, to the extent 
to which they are patients, that their therapeutic interests, 
even if not incidental, will be subordinated to scientific 
interests; (2) that it is problematic and indeterminate 
whether their welfare will be better served by placing their 
medical fate in the hands of a physician rather than an 
investigator; (3) that in opting for the care of a physician 
they may be better or worse off and for such and such 
reasons; ( 4) that clinical research will allow doctors to 
penetrate the mysteries of medicine's uncertainties about 
which treatments are best, dangerous, or ineffective; (5) 
that clinical research may possibly be in the patient's 
immediate best interest, perhaps promise benefits in the 
future, or provide no benefit, particularly if the patient is 
assigned to a control (placebo) arm of a study; (6) that 
research is governed by a research protocol and a research 
question and, therefore, his or her interests and needs will 
yield to the claims of science; and (7) that physician-
investigators will respect whatever decision the subject 
ultimately makes. 111 
To these I would add a few other suggestions. Much of the general 
infonnation discussed by Professor Katz should be included in a video 
shown at the beginning of the informed consent process. The video should 
clearly explain the difference between research and therapy and describe to 
subjects their obligation to provide meaningful consent. In this television 
age, people often find audio-visual aids to be an accessible and effective 
communication tool that is an essential supplement to written materials and 
verbal presentations. Educational videos have been successfully used by 
many doctors. In 1998, for example, the Foundation for Informed Medical 
Decision Making produced a video entitled "The PSA Decision: What 
109 For a detailed discussion of recommendations for the enhancement of IRB 
effectiveness see Sharona Hoffman, Continued Concern: Human Subject Protection, the 
Institutional Review Board, and Continuing Review, 68 TENN. L. REv. 725 (2001). 
110 Katz, supra note 92, at 34. 
111 /d. 
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You Need to Know," which was intended to assist asymptomatic men over 
50 in deciding whether to undergo prostate-specific antigen (PSA) tests. 112 
The informed consent process should also rndude a . thorough 
discussion between the potential subject and the investigator or a research 
nurse, in which all the details of the trial are verbally explained. 113 
Potential participants should then be quizzed to ascertain that they fully 
understand the information they have received and to determine whether 
they are able to articulate answers to specific questions. 114 The inform~d 
consent process should continue until the investigator is satisfied that the 
potential subject understands all necessary information. 115 Those who fail 
to demonstrate a satisfactory level of comprehension after the· investigator 
or a nurse has invested a reasonable amount of time and effort in the 
informed consent process should not be enrolled as human subjects. 116 
To facilitate reading comprehension, informed consent documents 
should be written in simple lan~uage that can be understood by people with 
an eighth grade reading level. 1 7 If at all possible, IRBs should include at 
least one member with expertise in reading comprehension or elementary 
education who could scrutinize informed consent forms to determine their 
readability and recommend simplifications where appropriate. 118 
112 THE PSA DECISION: WHAT You NEED To KNow, (The Foundation for Informed 
Medical Decision Making (1998)). 
113 See Riecken & Ravich, supra note 93. The article discusses a survey of 188 male 
veteran patients who were human subjects in research projects in four VA hospitals. Thirty 
seven principal investigators were also surveyed. Of investigators who were personally . 
responsible for explaining the study to patients, approximately half reported that they spent 
less than 15 minutes obtaining informed consent from patients, and a third stated that they 
spent between 15 and 30 minutes. Riecken & Ravich, supra note 93, at 345. Twenty-eight 
percent of research participants did not realize that they were enrolled in a clinical trial, and 
they were concentrated in the studies in which the investigators invested the shortest 
periods of time in the consent process. Riecken & Ravich, supra note 93, at 345. Only one 
investigator had no unaware participants. He had given e.ach potential subject a short 
examination after providing an explanation of the study. If the patient did not pass, the trial 
was described again. Riecken & Ravich, supra note 93, at 347. 
114 . See Katz, supra note 92, at 36-37. 
115 See Katz, supra note 92, at 36. 
116 See Riecken & Ravich, supra note at 93. 
117 Grossman., supra note 94, at 2212. The authors found that the typical consent 
form that describes a clinical oncology protocol is "too complex to be read by most patients 
and their families." The average person reads at approximately an eighth grade reading 
level, and the mean grade level required for comprehension of the forms that were studied 
was between 11.1 and 14.1, depending on the index used. See id. 
118 21 C.F.R. §56.108(c); 45 C.F.R. § 46.108(b). IRBs must include at least one 
community representative whose primary concerns are nonscientific. 21 C.F.R. §56.108(c); 
(continued) 
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C. Storage Of Blood And Tissue Samples For Future Genetic Testing 
Many clinical trials include blood tests or tissue biopsies. Once testing 
has been completed for purposes of the study, investigators often wish to 
store the blood or tissue samples for purposes of future genetic testing. 119 
It is difficult to obtain meaningful informed consent for unknown future 
studies because researchers cannot accurately describe the research that 
will be conducted or the data that will be sought. 
In addition, genetic testing raises important concerns about privacy and 
potential discrimination. 120 If confidentiality is not properly maintained 
and genetic data about an individual is disclosed to third parties, such as 
employers and insurers, theindividual might suffer discrimination. 121 For 
example, genetic testing might reveal that a person is susceptible to a 
particular cancer, leading employers who obtain these test results to 
decline to hire her and insurers to deny her coverage because of anticipated 
costs that will be generated by her likely poor health status in the future. 122 
Consequently, it is important that careful efforts be made to obtain 
informed consent for the storage of blood and tissue samples for purposes 
of future genetic testing. 123 Consent for tissue storage should be separate 
from consent for the underlying clinical trial, and thus, the subject should 
receive two consent documents and be required to provide two consent 
signatures for studies that contemplate future genetic testing. Subjects 
must be alerted to the fact that the issue of tissue storage is different from 
the issue of participation in the underlying trial and that it requires a 
separate decision-making process. 
The consent form should address how confidentiality will be 
safeguarded and inform subjects about whether their samples will be de-
identified. It should also disclose to participants that they will not 
personally benefit from future genetic testing in that researchers will not 
45 C.F.R. § 46.l08(b). The regulations do not specify what the community representative's 
nonscientific expertise should be. See id. In light of contemporary concerns about the 
readability of informed consent documents, however, IRBs would be wise to choose a 
layperson whose field of specialty is reading comprehension or elementary education. 
119 Goerge J. Annas, The Limits of State Laws to Protect Genetic Information, 345 N. 
ENGL. J. MED. 385, 387 (2001). 
120 !d. 
121 !d.; See also Mark A. Rothstein & Sharona Hoffinan, Genetic Testing, Genetic 
Medicine, and Managed Care, 34 WAKE FOREST L. REv. 849, 865-71. 
122 Annas, supra note 120. 
123 One commentator states that in reality what is being obtained is a waiver of 
informed consent, because the subject generally agrees not to be notified about or consent 
to future testing. Interview with Pilar Ossorio, Assistant Professor of Law, University of 
Wisconsin Law School (Nov. 30, 2001). 
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contact subjects or their doctors to provide test results. Furthermore, 
subjects should be informed that the research sponsor might profit from 
future research if it develops a new drug or therapy that is successfully 
marketed but that the individuals whose samples were utilized will not 
receive a share of the sponsor's earnings. 
Finally, the consent form should provide subjects with choices as to 
the type of research to be conducted using their samples. For example, 
participants in a clinical trial relating to preast cancer who agree to storage 
of their samples could be asked to select from among the following: 1) I 
agree to have my sample used for future genetic testing related to breast 
cancer; 2) I agree to have my sample used for future genetic testing related 
to diseases other than breast cancer; and 3) I agree to have my sample 
stored but wish the investigator to contact me for permission before any 
testing is conducted in the future. If subjects read, think about, and 
respond to specific questions, investigators can be reassured that 
participants have understood the choices they were required to make and 
have provided meaningful consent. 
VI. CONCLUSION 
Enhancement of protections for human subjects will undoubtedly 
impose added costs for clinical research. Increasing 1he number of IRB 
professionals will require funcling by private and. governinental research 
sponsors. 124 A conscientious effort to obtain meaningful consent may 
delay recruitment of subjects and completion of research. 125 A valid 
informed consent process mar, require several hours or even repeated 
conversations over a few days~ 26 Furthermore, if patients fully understand 
all components and risks of a protocol, they may more often refuse to 
enroll, making some studies difficult or, in rare cases, impossible to 
conduct. 127 These negative consequences, however, are outweighed by the 
advantages of enhancing the integrity of biomedical research, bolstering 
human subject protection, and reducing the likelihood of liability 
associated with clinical studies. 
124 See Katz, supra note 92; at 38. 
125 Katz, supra note 92, at 36. 
126 Riecken & Ravich, supra note 93, at 345-47~ 
127 See Gina Kolato & Kurt Eichenwald, Hope for Sale: A Special Report; Business 
Thrives on Unproven Care, Leaving Science Behind, N.Y. TIMES, Oct. 3, 1999, at Al 
(discussing the difficulties faced by some investigators who wish to recruit patients to 
participate in clinical trials involving treatments for serious illnesses such as cancer, heart 
failure, and Parkinson's disease). /d. 
